Hughes Sarah, Barbachano Yolanda, Ashley Sue, Yap Yoon-Sim, Popat Sanjay, Allen Mark, Della-Rovere Uccio Querci, Johnston Stephen, Smith Ian, O'Brien Mary
The Royal Marsden Hospital, Surrey, United Kingdom.
Breast J. 2008 Mar-Apr;14(2):158-63. doi: 10.1111/j.1524-4741.2007.00547.x. Epub 2008 Feb 25.
Mortality rates for breast cancer are improving in most countries. Life expectancy is also improving, and as age is the major risk factor for the development of breast cancer, we sought to determine whether survival of elderly women with breast cancer has improved over the past 20 years in our institution. In a retrospective study using a prospectively maintained database, we identified 950 women aged > or =70 years diagnosed with breast cancer between 1980 and 2000. Overall survival of patients was compared between two different time cohorts--those diagnosed from 1980 to 1990 and from 1991 to 2000--and between three age cohorts, 70-74, 75-79, and 80+ years. In all age groups, advanced stage, the need for mastectomy, and having chemotherapy were associated with a worse outcome on univariate analysis. Endocrine therapy (tamoxifen) was given to 60-70% of all age groups. After adjustment for clinical stage, we found no significant improvement in survival between the two time cohorts in any age groups. Compared with an age-matched group in the general population, these elderly breast cancer patients have a 62% increased risk of death. The results are likely to reflect lack of data to promote treatment guidelines. More clinical trials for older women are needed, if the benefits of recent advances in the management of this disease are to be extended to the over 70s. These data should, however, act as a benchmark for future audits.
大多数国家的乳腺癌死亡率都在下降。预期寿命也在提高,而且由于年龄是乳腺癌发病的主要风险因素,我们试图确定在过去20年里,我院老年乳腺癌患者的生存率是否有所提高。在一项使用前瞻性维护数据库的回顾性研究中,我们确定了950名年龄≥70岁、在1980年至2000年间被诊断为乳腺癌的女性。比较了两个不同时间段队列(1980年至1990年诊断的患者和1991年至2000年诊断的患者)以及三个年龄队列(70 - 74岁、75 - 79岁和80岁及以上)患者的总生存率。在所有年龄组中,单因素分析显示,晚期、需要进行乳房切除术以及接受化疗与较差的预后相关。所有年龄组中有60% - 70%的患者接受了内分泌治疗(他莫昔芬)。在对临床分期进行调整后,我们发现任何年龄组的两个时间段队列之间的生存率均无显著改善。与一般人群中年龄匹配的组相比,这些老年乳腺癌患者的死亡风险增加了62%。这些结果可能反映出缺乏推动治疗指南的数据。如果要将这种疾病管理方面的最新进展的益处扩展到70岁以上的人群,就需要针对老年女性开展更多的临床试验。然而,这些数据应作为未来审计的基准。